Liquid biopsy · curated MDI catalog

Liquid biopsy cancer tests

Liquid biopsy measures molecular signals in blood or other body fluids. The same sample type can be used for very different purposes, including screening, genomic profiling and MRD monitoring.

66 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • Avantect Ovarian Cancer Test — Cell-free DNA blood LDT intended as an aid to earlier ovarian-cancer detection in women at elevated risk.
  • Avantect Pancreatic Cancer Test — Blood-based multi-analyte, multiomic test intended to support earlier pancreatic cancer detection in elevated-risk patients.
  • BRCAplus — Guideline-based germline hereditary breast cancer panel.
  • CanCatch Custom — Tumor-informed personalized ctDNA MRD approach using WES baseline profiling and patient-specific mutation tracking.
  • Cancerguard — Multi-cancer early detection laboratory-developed test for adults 50–84; breast/prostate screening and precancer detection are outside the documented current use.
  • CancerNext — Guideline-based germline hereditary cancer panel.
  • CancerNext-Expanded — Germline hereditary-cancer panel; current vendor page reports 78 genes while recent official 77-gene materials require explicit version separation.
  • CancerVista — ctDNA liquid-biopsy in-house IVD for MRD detection, recurrence surveillance and therapy monitoring across solid tumors.
  • CanScan — Blood-based multi-cancer early detection test using low-depth WGS and AI integration of fragmentomic, genomic and inferred epigenomic cfDNA features.
  • Caris Assure — Whole-blood comprehensive molecular profiling for advanced solid tumors.
  • Caris ChromoSeq — Whole-genome/transcriptome profiling for diagnosed or suspected myeloid malignancies.
  • Caris Detect — Blood-based multi-cancer early detection LDT using whole-genome and whole-transcriptome sequencing with AI.
  • clonoSEQ — NGS-based clonotype assay for measurable/minimal residual disease assessment in lymphoid malignancies, with disease- and specimen-specific FDA-cleared contexts and additional LDT uses.
  • cobas EGFR Mutation Test v2 — FDA-approved real-time PCR EGFR companion diagnostic for NSCLC.
  • ColoHealth — Blood-based methylated SEPT9 colorectal cancer testing family; current ColoHealth Direct LDT and historical FDA device lineage are modeled separately.
  • EPISEEK — Blood-based multi-cancer early detection LDT analyzing abnormal DNA methylation signals associated with more than 60 cancer types.
  • FirstLook Lung — Blood-based cfDNA fragmentomics laboratory-developed test used as an adjunct in the lung-cancer screening pathway; not a replacement for LDCT.
  • Foresight CLARITY — Ultra-sensitive ctDNA molecular residual disease assay using PhasED-Seq phased-variant detection, with strong current use in B-cell lymphoma clinical programs.
  • FoundationOne Heme — DNA/RNA comprehensive genomic profiling LDT for hematologic neoplasms and other source-defined indications.
  • FoundationOne Liquid CDx — Blood-based 324-gene comprehensive genomic profiling and companion-diagnostic test for advanced solid tumors. Regulatory claims are PMA-, supplement-, biomarker-, therapy- and indication-scoped.
  • FoundationOne MRD — Tissue-informed ctDNA MRD assay for stage II-III breast cancer using tumor WGS and multiplex dPCR.
  • Galleri — Prescription-only multi-cancer early detection test.
  • Guardant Reveal — Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
  • Guardant360 Liquid CDx — Plasma cfDNA comprehensive genomic profiling and indication-specific companion diagnostic.
  • Haystack MRD — Tumor-informed ctDNA molecular residual disease assay for solid tumors using WES-derived personalized panels tracking up to 50 variants.
  • Invitae Common Hereditary Cancers Panel — NGS germline panel for common hereditary cancer predisposition.
  • Invitae Hereditary Breast and Gyn Cancers Panel — NGS germline panel for hereditary breast and gynecologic cancer predisposition.
  • Invitae Hereditary Colorectal Cancer Guidelines-based Panel — NGS germline panel for hereditary colorectal cancer predisposition.
  • Invitae Hereditary Pancreatic Cancer Panel — NGS germline panel for hereditary pancreatic cancer predisposition.
  • Invitae Hereditary Prostate Cancer Panel — NGS germline panel for hereditary prostate cancer predisposition.
  • Invitae Personalized Cancer Monitoring — Tumor-informed personalized ctDNA monitoring assay for solid tumors.
  • Labcorp Plasma Detect Genome MRD — Tumor-informed whole-genome sequencing ctDNA MRD test currently offered for stage III colon cancer baseline and monitoring.
  • LiquidHALLMARK — Prescription plasma liquid-biopsy assay detecting ctDNA and ctRNA for molecular profiling and treatment selection in advanced cancer.
  • LucenceINSIGHT — Prescription blood-based multi-cancer early detection family using ctDNA and viral DNA with machine-learning tissue localization.
  • LymphoVista — ctDNA sequencing in-house IVD for lymphoma genotyping, MRD assessment and longitudinal monitoring.
  • MSK-ACCESS — Institutional ultra-deep cfDNA sequencing assay for noninvasive genomic profiling and disease monitoring; current panel covers 146 genes.
  • MSK-IMPACT — Tumor-normal targeted DNA sequencing for comprehensive tumor profiling.
  • MyRisk — Germline hereditary-cancer panel; current documented configuration contains 63 clinically recommended genes and must not inherit analytical metrics from historical 25-gene validation.
  • NavDx — Blood-based TTMV-HPV DNA laboratory-developed test used in HPV-driven cancer management and post-treatment recurrence surveillance.
  • NEO PanTracer LBx — 514-gene ctDNA liquid-biopsy comprehensive genomic profiling assay for advanced pan-solid tumors, including MSI-H and bTMB.
  • NeXT Personal Dx — Tumor-informed personalized ctDNA LDT using WGS-derived patient-specific signatures for MRD, recurrence and treatment-response monitoring.
  • Nodify CDT — Blood autoantibody classifier that raises malignancy risk for selected pulmonary nodules.
  • Nodify XL2 — Blood-based proteomic classifier to identify lung nodules likely benign.
  • Northstar Response — Tissue-free methylated-ctDNA liquid biopsy for quantitative treatment-response monitoring across advanced solid tumors.
  • Northstar Select — 102-gene plasma ctDNA comprehensive genomic profiling assay for therapy selection in advanced solid tumors.
  • Oncodetect MRD — Tumor-informed ctDNA molecular residual disease test used across solid tumors; current commercial configuration tracks up to 200 tumor-specific variants.
  • OncoExTra — Whole-exome and whole-transcriptome tumor profiling with matched-normal subtraction for advanced solid tumors.
  • Oncoguard Liver — Blood-based aid for HCC detection in an at-risk surveillance population.
  • OneTest for Cancer — Blood-based multi-cancer early detection LDT combining multiple serum tumor biomarkers with a machine-learning risk algorithm.
  • OverC Multi-Cancer Detection — Blood-based cfDNA methylation multi-cancer early detection test with six-cancer current product scope; jurisdiction-specific regulatory status.
  • PanTum Detect — Whole-blood multi-cancer screening aid detecting Apo10/DNaseX and TKTL1 signals in monocytes using EDIM/flow-cytometry-based methodology.
  • PGDx elio plasma focus Dx — FDA-authorized plasma cfDNA next-generation sequencing tumor-profiling test for patients already diagnosed with solid malignant neoplasms.
  • Precise MRD — Tumor-informed whole-genome sequencing MRD assay tracking up to 1,000 patient-specific variants for treatment and recurrence monitoring.
  • PredicineCARE — CLIA-certified 200-gene cfDNA assay for treatment selection and comprehensive molecular profiling in solid tumors.
  • ProVue Lung — Proteomics-based blood LDT designed to complement LDCT lung-cancer screening in high-risk adults.
  • RaDaR ST — Personalized tumor-informed ctDNA MRD assay for solid tumors; current ST generation uses WES tumor profiling and tracks up to 48 patient-specific mutations.
  • Shield — Blood-based colorectal cancer screening test.
  • Signatera — Personalized tumor-informed circulating tumor DNA molecular residual disease test family. Includes the FDA-authorized Signatera CDx MIBC companion-diagnostic configuration and broader laboratory-developed clinical uses that remain separately scoped.
  • SimpleScreen CRC — FDA-approved blood-based colorectal cancer screening test for average-risk adults age 45 and older.
  • SimpleScreen Lung — Blood-based multiomic LDT intended to increase lung-cancer screening participation among eligible high-risk adults not completing LDCT.
  • SPOT-MAS 10 — Blood-based multi-cancer screening test using cfDNA methylation and fragmentomic signals with machine learning.
  • Tempus xF+ — 523-gene plasma liquid-biopsy comprehensive genomic profiling assay for therapy selection and molecular profiling in advanced cancer.
  • Tempus xM — Tumor-naive liquid-only MRD assay combining methylation- and variant-based workflows for stage II-III colorectal cancer.
  • Tempus xT CDx — 648-gene tissue comprehensive genomic profiling companion diagnostic.
  • therascreen PIK3CA RGQ PCR Kit — FDA-approved real-time PCR PIK3CA companion diagnostic for breast cancer.
  • Trucheck Intelli — Blood-based multi-cancer early detection test that detects circulating tumor cells and reports likely tissue/tumor context across many solid tumors.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance